XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On July5, 2017, we entered into a Second Amendment to Lease (the “Amendment”) with 111 Lemon Investors LLC (the “Landlord”), which amended that certain Lease dated as of January1, 2015 (the “Original Lease”) by and between us and BF Monrovia, LLC (“Original Landlord”), as amended by that certain Amendment to Lease dated as of January26, 2015, whereby we leased from Original Landlord that certain space containing approximately 24,573 rentable square feet, located on the second floor (the “Existing Premises”) of that certain building located at 111 West Lemon Street, Monrovia, California 91016 (the “Building”). The Amendment amends the Original Lease to expand the Existing Premises to include approximately 23,652 rentable square feet, comprising the entire third floor of the Building (the “Expansion Space”). The Amendment, including the expansion of the Existing Premises to include the Expansion Space, is scheduled to commence on August1, 2017 (the “Expansion Commencement Date”) and will terminate 62 months following the Expansion Commencement Date. The initial base monthly rent for the Expansion Space, which will be paid by us separate and apart from the base monthly rent payable for the Existing Premises under the Original Lease, is $50,851.80 and will increase approximately three percent annually. Additional rent may be due for excess operating and tax expenses to Section5 of the Amendment.

A copy of the Amendment is filed as Exhibit99.1 to this current report and the description of the terms of the Amendment contained herein is qualified in its entirety by reference to such exhibit.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Second Amendment to Lease, dated July5, 2017, by and between Xencor,Inc. and 111 Lemon Investors LLC


Xencor Inc Exhibit
EX-99.1 2 a17-17112_1ex99d1.htm EX-99.1 Exhibit 99.1   SECOND AMENDMENT TO LEASE   This SECOND AMENDMENT TO LEASE (this “Amendment”) is made and effective as of July 5,…
To view the full exhibit click here

About XENCOR,INC. (NASDAQ:XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. Its clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. Its oncology product candidates are in preclinical stage, which include XmAb14045 and XmAb13676. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 and XmAb13551.